• AssureRx Health Inc., of Cincinnati, closed an $11 million Series B financing round to expand direct sales and marketing of its genetic diagnostic product, GeneSightRx. Claremont Creek Venture and Sequoia Capital led the round, with participation by Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech and Allos Ventures. GeneSightRx is being developed as a test to predict a patient's response to psychotropic medication, and to help physicians choose the best antidepressant or antipsychotic for each patient.